SCHEMBL1346809

SCHEMBL1346809

NCc1cccc(-c2cccc(C3CN(S(=O)(=O)c4ccccc4)CCN3c3ccccc3)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
USP2 O75604 3/20 0.40
MAPK1 P28482 2/20 0.40
HIF1A Q16665 2/20 0.40
HSD17B10 Q99714 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 1/20 0.40
KDM4E B2RXH2 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C1 Q04828 1/20 0.39
GCKR Q14397 2/20 0.38
LSS P48449 1/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
CYP3A4 P08684 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA4 P22748 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1346988 0.84 NR1H2 (0.44) ALDH1A1USP2MAPK1HIF1AHSD17B10
SCHEMBL1348821 0.79 CCR5 (0.44) ALDH1A1SMN1; SMN2KDM4EAKR1C3AKR1C1
SCHEMBL15841672 0.79 CCR5 (0.44) ALDH1A1SMN1; SMN2KDM4EAKR1C3AKR1C1
SCHEMBL1459075 0.75 HTR6 (0.42) ALDH1A1HPGDKDM4ENR1H2CA1
SCHEMBL1348530 0.73 LMNA (0.48) MAPK1HSD17B10AKR1C3AKR1C1NR1H2
SCHEMBL1459473 0.69 NR1H2 (0.41) AKR1C3AKR1C1NR1H2NR1H3
SCHEMBL27839600 0.68 LMNA (0.39)
SCHEMBL1349030 0.66 NR1H2 (0.41) ALDH1A1USP2MAPK1HIF1AHSD17B10
SCHEMBL27519960 0.64 USP5 (0.60) ALDH1A1USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL1349414 0.64 CTSG (0.47) ALDH1A1USP2MAPK1HIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2288594-B1 IMIDAZOLIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-07-02 EP claimed
EP-2288594-A1 IMIDAZOLIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-03-02 EP claimed
US-20090312382-A1 NOVEL IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US claimed
WO-2009150109-A1 IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 WO claimed
EP-2288594-B1 IMIDAZOLIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-07-02 EP disclosed
US-8063088-B2 Imidazolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
EP-2288594-A1 IMIDAZOLIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-03-02 EP disclosed
US-20090312382-A1 NOVEL IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed
WO-2009150109-A1 IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312382-A1 NOVEL IMIDAZOLIDINE DERIVATIVES NR1H2, NR1H3, NR1D2 ALDH1A1 1243/4885USP2 4655/4885MAPK1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.